XML 22 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
¥ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
CNY (¥)
¥ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
CNY (¥)
¥ / shares
shares
Dec. 31, 2021
CNY (¥)
¥ / shares
shares
Revenues, net of value-added tax ¥ 537,402 $ 75,691 ¥ 472,085 ¥ 485,633
Cost of revenues (614,010) (86,481) (624,494) (542,530)
Gross loss (76,608) (10,790) (152,409) (56,897)
Operating expenses:        
Selling expenses (56,299) (7,930) (61,479) (53,675)
General and administrative expenses (330,078) (46,491) (311,160) (347,746)
Impairment of long-lived assets | ¥ 0   0 0
Operating loss (462,985) (65,211) (525,048) (458,318)
Interest expense (including interest expense to related party amounting to RMB13,532, RMB16,790 and RMB14,308 (US$2,015) for the years ended December 31, 2021, 2022 and 2023, respectively) (165,669) (23,334) (120,357) (73,789)
Foreign exchange (loss) gain, net 10,149 1,429 54,982 (19,925)
(loss) Gain on disposal of long-lived assets 62 9 (3)  
Interest income (including interest income from related party amounting to RMB3,447, RMB6,961 and RMB6,813 (US$960) for the years ended December 31, 2021, 2022 and 2023, respectively) 10,832 1,526 10,021 5,894
Change in fair value of derivative liability 5,207 733 1,015 (39)
Income from equity method investments 20,789 2,928 17,647 18,163
Loss on disposal of a subsidiary (638) (90) (61,546) 0
Other expenses, net (10,839) (1,527) (216,607) (1,223)
Gain on sale of partial interests in an equity method investment 37,498 5,281 0 0
Loss before income tax (555,594) (78,256) (839,896) (529,237)
Income tax benefit 24,573 3,461 70,906 6,565
Net loss (531,021) (74,795) (768,990) (522,672)
Net loss attributable to noncontrolling interests 233,363 32,868 279,329 251,245
Net loss attributable to Concord Medical Services Holdings Limited ¥ (297,658) $ (41,927) ¥ (489,661) ¥ (271,427)
Loss per share for Class A and Class B ordinary shares:        
Basic | (per share) ¥ (2.27) $ (0.32) ¥ (3.74) ¥ (6.26)
Diluted | (per share) ¥ (2.27) $ (0.32) ¥ (3.74) ¥ (6.26)
Weighted average number of class A and class B ordinary shares outstanding:        
Basic 131,053,858 131,053,858 131,053,858 131,053,858
Diluted 131,053,858 131,053,858 131,053,858 131,053,858
Other comprehensive income (loss), net of tax of nil        
Foreign currency translation, net tax of nil ¥ (6,480) $ (913) ¥ (53,964) ¥ 14,821
Unrealized losses on available-for-sale securities, net (31,173) (4,391)    
Total other comprehensive income (loss), net of tax (37,653) (5,304) (53,964) 14,821
Comprehensive loss (568,674) (80,099) (822,954) (507,851)
Comprehensive loss attributable to noncontrolling interests (233,363) (32,868) (279,329) (251,245)
Comprehensive loss attributable to Concord Medical Services Holdings Limited (335,311) (47,231) (543,625) (256,606)
Equipment leasing revenues        
Revenues, net of value-added tax 16,737 2,357 21,966 42,484
Cost of revenues (14,824) (2,088) (18,905) (40,539)
Services and other revenues        
Revenues, net of value-added tax 420,201 59,184 364,412 383,828
Cost of revenues (500,068) (70,433) (518,500) (441,510)
Medicine income        
Revenues, net of value-added tax 100,464 14,150 85,707 59,321
Cost of revenues ¥ (99,118) $ (13,960) ¥ (87,089) ¥ (60,481)